New Guidelines for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: Rethinking Hematopoietic Stem Cell Transplantation

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Unfollow podcast failed

New Guidelines for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: Rethinking Hematopoietic Stem Cell Transplantation

Listen for free

View show details

LIMITED TIME OFFER | £0.99/mo for the first 3 months

Premium Plus auto-renews at £8.99/mo after 3 months. Terms apply.

About this listen

Jeffrey Cohen, MD, Professor, Cleveland Clinic Lerner College of Medicine, and Director of the Experimental Therapeutics Program at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic, Cleveland, OH, reviews the latest international guidelines from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and EBMT on the use of autologous hematopoietic stem cell transplantation (AHSCT) in relapsing multiple sclerosis and neuromyelitis optica spectrum disorder.

No reviews yet